Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

PRG Nutraceuticals UK Launch

1 Oct 2009 10:34

RNS Number : 0408A
ReGen Therapeutics PLC
01 October 2009
 



1 October 2009

For immediate release

ReGen Announces PRG Nutraceuticals Limited UK Launch

ReGen Therapeutics Plc ('ReGen' or the 'Company') is pleased to announce that it has been notified by PRG Nutraceuticals Limited that it has launched Colostrinin™* as 'MemoryAid' in the UK.

Announcing the launch, PRG Managing Director Dr Peter Garrod said:-

"Every day we hear more evidence of how the population faces a terrible future as our brains become increasingly affected by conditions associated with getting old. MemoryAid contains a complex that we believe will help people to fight the onset of the problems that result from our brains undergoing the normal ageing process. Many years of research into the complex has shown that it promotes antioxidant activity, can reduce the toxicity of beta amyloid and protects the brain against the damaging effects of free radicals, all of which manifest themselves in the problems that occur as our brains naturally age. The complex has also been shown to increase the average lifespan of living cells and reduces premature ageing, which will also benefit consumers.

MemoryAid is targeted at a wide spectrum of people, both the older community, who may already be noticing that their brains are not functioning in the manner they are normally accustomed to, and at younger adults, who just want to protect themselves against memory deterioration in the future.

We are very excited by the benefits of MemoryAid and believe that it has a bright future on everyone's breakfast table."

MemoryAid is available on the internet at www.memoryaid.com or by contacting PRG on 01580 891349 or mobile 07785 740421.  

MemoryAid

Support for healthy brain ageing

Maintains normal mental function and supports healthy brain ageing.

Increases the average lifespan of living cells.

Reduces the aggregation and toxicity of beta amyloid, a feature of neurodegenerative conditions.

Protects the brain against the damaging effects of many free radicals

*Colostrinin™ is a proline-rich polypeptide complex that maintains normal mental function and supports healthy brain ageing.

For further information:

Dr Peter Garrod

PRG Nutraceuticals Ltd

Tel. 01580 891349 / 07785 740421

Percy Lomax ReGen Therapeutics Plc Tel No 020 7153 4920

Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel No 020 7628 3396

Nick Bealer/David Scott Alexander David Tel No 020 7448 9820 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGCBDGIDGGGCB
Date   Source Headline
28th May 20197:00 amRNS9th Annual LD Micro Invitational
7th May 20197:00 amRNSNotice of AGM
2nd May 20197:00 amRNSDirector/PDMR Shareholding
1st May 20197:00 amRNSUpdate on IND Application
25th Apr 20195:00 pmRNSDirector/PDMR Shareholding
24th Apr 201912:55 pmRNSReissue: Interim Clinical Data
24th Apr 20197:00 amRNSInterim Clinical Data
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
4th Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSIND Application Submitted for NASH Oral Treatment
7th Feb 20197:00 amRNSDirectorate Change
11th Dec 20187:00 amRNSExercise of Warrants & Issue of Equity
3rd Dec 20187:00 amRNSMilciclib HCC Phase IIa Trial Enrollment Completed
28th Nov 20187:00 amRNSForalumab: Phase 1 Trial with Nasal Administration
27th Nov 20187:00 amRNSHolding(s) in Company
26th Nov 20187:00 amRNSStatement re: ADSs
23rd Nov 20185:00 pmRNSClosing of Offering and Total Voting Rights
20th Nov 20187:30 amRNSDiscounted exercise prices of outstanding warrants
20th Nov 20187:00 amRNSOffer Pricing, Nasdaq Listing & Loan Conversion
18th Oct 20187:15 amRNSAmended Registration Statement filed with the SEC
16th Oct 20187:00 amRNSMilciclib synergistic activity presented at AASLD
25th Sep 20187:00 amRNSTiziana announces Offering & Application to Nasdaq
24th Sep 20187:03 amRNSInterim Results for Six Months Ended 30 June 2018
24th Sep 20187:00 amRNSU.S. FDA Approval IND Nasal Foralumab Phase 1
13th Sep 20181:05 pmRNSPDMR Dealing
12th Sep 20187:00 amRNSPDMR dealings
11th Sep 20187:00 amRNSPDMR Dealing
24th Aug 20187:00 amRNSPDMR Dealing
21st Aug 20187:00 amRNSPDMR dealings
20th Aug 20187:00 amRNSPDMR Dealing
17th Aug 20187:00 amRNSPDMR Dealing
16th Aug 20189:00 amRNSFiling of Investigational New Drug application
27th Jul 20187:00 amRNSUS Registration Statement for Proposed Offering
25th Jun 201810:49 amRNSResult of AGM
7th Jun 20187:01 amRNSAppointment of Broker
7th Jun 20187:00 amRNSFinal Results
1st Jun 20187:00 amRNSNotice of AGM
23rd May 20184:40 pmRNSSecond Price Monitoring Extn
23rd May 20184:35 pmRNSPrice Monitoring Extension
16th May 20187:00 amRNSMilciclib Phase 2a Trial - Tolerability Update
1st May 20183:00 pmRNSGrant of Options - Director Dealing
27th Apr 20187:00 amRNSIssue of Equity
19th Apr 20187:00 amRNSSubscription
16th Apr 20187:25 amRNSLicense Agreement
9th Apr 20188:25 amRNSPresentation at ASCO 3 June 2018
5th Apr 20187:00 amRNSAppointment of Broker
4th Apr 20187:00 amRNSAppointment of Director
5th Mar 20187:00 amRNSPlacing to raise £600,000 and issue of equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.